目的 探討十味龍膽花顆粒聯(lián)合布地奈德福莫特羅粉治療支氣管哮喘的臨床療效。方法 選擇2018年1月-2019年1月在北京懷柔醫(yī)院治療的支氣管哮喘患者82例，根據(jù)用藥的差別分為對照組（41例）和治療組（41例）。對照組給予布地奈德福莫特羅粉吸入劑，2吸/次，2次/d；治療組在對照組的基礎上口服十味龍膽花顆粒，3 g/次，3次/d。兩組患者均治療2周。觀察兩組患者臨床療效，同時比較治療前后兩組患者WHOQOL-BREF、LCQ、MARS-A和C-ACT評分，血清基質(zhì)金屬蛋白酶組織抑制劑-1（TIMP-1）、半胱氨酰白三烯（CysLTs）、降鈣素原（PCT）、白細胞介素-4（IL-4）和白細胞介素-6（IL-6）水平，以及一秒用力呼氣容積（FEV1）、用力肺活量（FVC）和最大呼氣流量（PEF）水平。結果 治療后，對照組臨床有效率為80.49%，顯著低于治療組的97.56%，兩組比較差異有統(tǒng)計學意義（P<0.05）。經(jīng)治療，兩組患者LCQ、MARS-A、C-ACT和WHOQOL-BREF評分均明顯升高（P<0.05），且治療組患者這些評分明顯高于對照組（P<0.05）。經(jīng)治療，兩組患者血清TIMP-1、CysLTs、PCT、IL-4、IL-6水平均明顯降低（P<0.05），且治療組患者這些血清學指標水平明顯低于對照組（P<0.05）。經(jīng)治療，兩組患者FEV1、FVC、PEF水平均明顯升高（P<0.05），且治療組患者這些肺功能指標明顯好于對照組（P<0.05）。結論 十味龍膽花顆粒聯(lián)合布地奈德福莫特羅粉吸入劑治療支氣管哮喘可有效改善患者臨床癥狀，促進肺功能改善，促進患者生活質(zhì)量提高，具有一定的臨床推廣應用價值。

Objective To explore the clinical efficacy of Shiwei Longdanhua Granules combined with budesonide formoterol in treatment of bronchial asthma. Methods Patients (82 cases) with bronchial asthma in Beijing Huairou Hospital from January 2018 to January 2019 were divided into control (41 cases) and treatment (41 cases) groups based on different treatments. Patients in the control group were administered with Budesonide and Formoterol Fumarate Powder for inhalation, 2 inhalation/time, twice daily. Patients in the treatment group were po administered with Shiwei Longdanhua Granules on the basis of the control group, 3 g/time, three times daily. Patients in two groups were treated for 2 weeks. After treatment, the clinical efficacy was evaluated, and the WHOQOL-BREF, LCQ, MARS-A and C-ACT scores, the serum levels of TIMP-1, CysLTs, PCT, IL-4 and IL-6, and the FEV1, FVC, PEF levels in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control group was 80.49%, which was significantly lower than 97.56% in the treatment group, and there were differences between two groups (P<0.05). After treatment, the WHOQOL-BREF, LCQ, MARS-A, and C-ACT scores in two groups were significantly increased (P<0.05), and these scores in the treatment group were significantly higher than those in the control group (P<0.05). After treatment, the serum levels of TIMP-1, CysLTs, PCT, IL-4, and IL-6 in two groups were significantly decreased (P<0.05), and these serological indexes in the treatment group were significantly lower than those in the control group (P<0.05). After treatment, the FEV1, FVC and PEF levels in two groups were significantly increased (P<0.05), and these pulmonary function indexes in the treatment group were significantly better than those in the control group (P<0.05). Conclusion Shiwei Longdanhua Granules combined with budesonide formoterol in treatment of bronchial asthma can effectively improve the clinical symptoms, promote the improvement of lung function and the quality of life, which has a certain clinical application value.

R974